Outcomes Research in Review

Quality of Life After Treatment of Chronic Total Occlusions with Revascularization versus Optimal Medical Therapy

Werner GS, Martin-Yuste V, Hildick-Smith V, et al; EUROCTO trial investigators. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J. 2018;39:2484-2493.


 

References

Study Overview

Objective. To compare the benefit of percutaneous coronary intervention (PCI) plus optimal medical therapy (OMT) versus OMT alone on the health status of patients with chronic total occlusions (CTOs).

Design. Multicenter, open-label, prospective randomized control trial.

Setting and participants. 396 patients with at least 1 CTO were assigned to PCI or OMT with a 2:1 randomization ratio.

Main outcome measures. The primary endpoint was the change in health status as assessed by the Seattle Angina Questionnaire (SAQ) between baseline and 12-month follow-up.

Main results. At 12 months, greater improvement of 3 SAQ domains was observed with PCI compared to OMT: angina frequency (5.23, 95% confidence interval [CI], 1.75-8.31, P = 0.0003), physical limitation (P = 0.02), and quality of life (6.62, 95% CI 1.78-11.46, P = 0.0007). More patients in the PCI group than in the OMT group had complete freedom from angina (71.6% vs. 57.8%, P = 0.008). There were no occurrences of periprocedural death or myocardial infarction.

Conclusion. Among patients with stable angina and CTO, PCI leads to significant health status improvement compared with OMT alone.

Commentary

CTOs are present in 15% to 25% of patients undergoing coronary angiogram1 and are associated with increased mortality.2 The benefits of successful CTO intervention observed in multiple large-scale registries include improvement in quality of life, left ventricular function, and survival as well as avoidance of coronary bypass surgery. The main indication for CTO intervention is improvement in quality of life,3 although this has not been confirmed by a randomized controlled trial comparing medical therapy to CTO-PCI.

Pages

Recommended Reading

Risk score validated for major NSAID adverse events
Journal of Clinical Outcomes Management
Data support revising ASCVD cardiovascular risk threshold
Journal of Clinical Outcomes Management
TIA and Stroke May Affect Risk of Subsequent Events Differently in Patients With Atrial Fibrillation
Journal of Clinical Outcomes Management
Exercise improves outcomes for patients with heart failure and OSA
Journal of Clinical Outcomes Management
New cholesterol, physical activity guidelines on tap at AHA 2018
Journal of Clinical Outcomes Management
Apixaban is safest effective DOAC for stroke prevention in Afib, per AHRQ report
Journal of Clinical Outcomes Management
Expert highlights rare causes of stroke to keep in mind
Journal of Clinical Outcomes Management
Tested: U.S. News & World Report hospital rankings
Journal of Clinical Outcomes Management
Teva recalls valsartan-containing combo pills
Journal of Clinical Outcomes Management
Heart disease remains the leading cause of death in U.S.
Journal of Clinical Outcomes Management